Skip to main content

Table 4 Breast

From: Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis

Author Cases n Controlsa/Cohortb Source population Exposure definition Exposure assessment Drug RR 95% CI
Sharpe et al. [44] 5,882 23,517a Population based >2 tablets/week during years 2 – 5 before index date Automated Database NSAIDs (4%) 0.76 0.63–0.92
Harris et al. [33] 744 767a Hospital based >3 tablets/week during more than 5 years Personal Interview NSAIDs (16%) 0.6 0.4–0.8
Harris et al. [34] 511 1,534a Hospital based >3 tablets/week for at least 1 year Personal Interview Aspirin (12%) 0.69 0.46–0.99
       NSAIDs (28%) 0.66 0.52–0.83
Coogan et al. [25] 6,558 2,925a Hospital based >4 days/week for >3 months. Personal Interview Aspirin (N.R.) 0.7 0.5–0.8
     Continuing use during 1 year of lag time   NA-NSAIDs (N.R.) 0.8 0.6–1.1
       NSAIDs (7%) 0.7 0.6–0.8
Langman et al. [36] 3,105 9,772a Population based >7 prescriptions during months 13–36 before index date Automated Database NSAIDs (6%) 1.10 0.92–1.30
Cotterchio et al. [27] 3,133 3,062a Population based Daily use for more than two months. 1 year before start date excluded Mailed Questionnaire Aspirin (14%) 0.73 0.61–0.87
       NA-NSAIDs (11%) 0.79 0.66–0.96
       NSAIDs (26%) 0.76 0.66–0.88
Meier et al. [61] 3,706 14,155a Population based ≥30 prescriptions Automated Database NSAIDs (8%) 1.0 0.8–1.1
Rosenberg et al. [56] 4,485 4,906a Hospital based >3 days/week for >3 months 1.5 years of lag timev Personal Interview NSAIDs (6%) 0.8 0.6–1.0
Neugut et al. [62] 252 176a Hospital based Chronic aspirin use Medical Records Aspirin (9%) 0.80 0.35–1.80
Friedman et al. [20] NR 143,574b Cohort ever use Medical Records Aspirin (2%) 0.20 0.05–0.80
       NA-NSAIDs» (3%) 0.50 0.28–0.88
Johnson et al. [58] 938 27,616b Cohort >5 times per week Mailed questionnaire Aspirin (21%) 0.71 0.58–0.87
       NA-NSAID (13%) 1.01 0.83–1.25
Egan et al. [29] 2,414 89,528b Cohort >2 tablets/week reported in 4 consecutive questionnaires Mailed Questionnaire Aspirin (15%) 1.01 0.80–1.27
       NA-NSAIDs (4%) 0.95 0.78–1.17
Harris et al. [35] 393 32,505b Cohort >4 tablest/week at start date In-hospital Questionnaire Aspirin (13%) 0.64 0.45–0.90
       NSAIDs (25%) 0.57 0.44–0.74
Paganini-Hill et al. [40] 214 8,881b Cohort Daily use of aspirin for an undefined time Mailed Questionnaire Aspirin (15%) 1.05§ 0.73–1.50
Thun et al. [46] NR. 344,350b Cohort More than 16 times per month for at least one year Mailed Questionnaire Aspirin (11%) 0.88 0.62–1.24
Schreinemachers et al. [43] 147 7,489b Cohort Ever use of aspirin in the 30 days prior to start date Personal Interview Aspirin (64%) 0.70 0.50–0.96
  1. Prevalence of exposure among controls/cohort; §Crude estimate calculated from data provided in the original manuscript; For NA – NSAIDs only the baseline questionnaire was considered; includes only Fiorinal (aspirin, phenacetin, caffeine and butalbital combination); » indomethacin only.